Illumina
Trade Illumina 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
ILMN Key Statistics
Stock Snapshot
The current Illumina(ILMN) stock price is $140.45, with a market capitalization of 21.46B. The stock trades at a price-to-earnings (P/E) ratio of 33.64.
During the trading session on 2026-01-09, Illumina(ILMN) shares reached a daily high of $145.80 and a low of $139.79. At a current price of $140.45, the stock is +0.5% higher than the low and still -3.7% under the high.
Trading volume for Illumina(ILMN) stock has reached 1.07M, versus its average volume of 1.33M.
The stock's 52-week range extends from a low of $68.70 to a high of $153.06.
The stock's 52-week range extends from a low of $68.70 to a high of $153.06.
ILMN News
Claim 70% Off TipRanks Premium An announcement from Illumina ( (ILMN) ) is now available. On January 8, 2026, Illumina announced that veteran genomics leader...
Eric Green, a former NIH director, is expected to become the chief medical officer of Illumina (ILMN), Jared Whitlock of Endpoints News reported. Claim 70% Off...
Illumina (ILMN) has drawn fresh investor attention after rolling out Connected Multiomics, a cloud platform that pulls together genomics, proteomics, transcript...
Analyst ratings
39%
of 23 ratingsMore ILMN News
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Illumina (ILMN) to $155 from $142 and keeps an Outperform rating on the shares. Recovering en...
Illumina has recently moved forward with separating its cancer-diagnostics unit Grail, a step aimed at resolving regulatory pressure and sharpening its focus on...